PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22025881-8	2011	Meanwhile, sorafenib could also inhibit Akt phosphorylation, and both the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and Akt knockdown resulted in Y705 dephosphorylation, indicating that Y705 dephosphorylation by sorafenib was mediated by inhibiting the PI3K/Akt pathway.	Sorafenib	11-20	AKT serine/threonine kinase 1	Rattus norvegicus	40-43	
24976727-10	2014	Immunoblot analysis showed that sorafenib and sunitib, but not erlotinib, efficiently blocked activation of the AKT pathway, while all three drugs displayed little effect on phosphorylation of ERK1/2.	Sorafenib	32-41	AKT serine/threonine kinase 1	Rattus norvegicus	112-115	
23043394-10	2013	Sorafenib attenuated pulmonary VEGF mRNA and VEGF, VEGFR-2 (VEGF receptor 2), phospho-VEGFR-2 and Akt protein expression.	Sorafenib	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	98-101	
29541403-2	2018	The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance.	Sorafenib	132-141	AKT serine/threonine kinase 1	Rattus norvegicus	4-7	
29541403-2	2018	The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance.	Sorafenib	132-141	AKT serine/threonine kinase 1	Rattus norvegicus	179-182	
28566435-3	2017	Therefore, we assess efficacy of the allosteric AKT inhibitor ARQ 092 compared with untreated control and standard treatment, sorafenib, in vitro and in vivo ARQ 092 blocked phosphorylation of AKT in vitro and strongly inhibited cell growth with significantly higher potency than sorafenib.	Sorafenib	280-289	AKT serine/threonine kinase 1	Rattus norvegicus	193-196	
22428038-8	2012	CONCLUSIONS: Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop compromises the anti-tumor activity of rapamycin in HCC, and blockade of this feedback loop by sorafenib is an attractive approach to improve the anti-tumor effect of rapamycin, particularly in preventing or treating HCC recurrence after liver transplantation.	Sorafenib	192-201	AKT serine/threonine kinase 1	Rattus norvegicus	32-35	
22025881-8	2011	Meanwhile, sorafenib could also inhibit Akt phosphorylation, and both the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and Akt knockdown resulted in Y705 dephosphorylation, indicating that Y705 dephosphorylation by sorafenib was mediated by inhibiting the PI3K/Akt pathway.	Sorafenib	11-20	AKT serine/threonine kinase 1	Rattus norvegicus	134-137	
22025881-8	2011	Meanwhile, sorafenib could also inhibit Akt phosphorylation, and both the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and Akt knockdown resulted in Y705 dephosphorylation, indicating that Y705 dephosphorylation by sorafenib was mediated by inhibiting the PI3K/Akt pathway.	Sorafenib	11-20	AKT serine/threonine kinase 1	Rattus norvegicus	134-137	
22025881-8	2011	Meanwhile, sorafenib could also inhibit Akt phosphorylation, and both the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and Akt knockdown resulted in Y705 dephosphorylation, indicating that Y705 dephosphorylation by sorafenib was mediated by inhibiting the PI3K/Akt pathway.	Sorafenib	226-235	AKT serine/threonine kinase 1	Rattus norvegicus	134-137	
22025881-8	2011	Meanwhile, sorafenib could also inhibit Akt phosphorylation, and both the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and Akt knockdown resulted in Y705 dephosphorylation, indicating that Y705 dephosphorylation by sorafenib was mediated by inhibiting the PI3K/Akt pathway.	Sorafenib	226-235	AKT serine/threonine kinase 1	Rattus norvegicus	134-137	
22025881-10	2011	CONCLUSION: Sorafenib inhibits growth and metastasis of HCC in part by blocking the MEK/ERK/STAT3 and PI3K/Akt/STAT3 signaling pathways, but independent of JAK2 and SHP2 activation.	Sorafenib	12-21	AKT serine/threonine kinase 1	Rattus norvegicus	107-110	
20447716-8	2010	Sorafenib inhibited the phosphorylation of ERK, Akt and 70-kDa ribosomal S6 kinase (p70S6K), both in vitro and in vivo.	Sorafenib	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	48-51